This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
by Zacks Equity Research
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
by Zacks Equity Research
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
by Zacks Equity Research
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
by Zacks Equity Research
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
by Zacks Equity Research
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
by Zacks Equity Research
Kiniksa Pharmaceuticals International, plc (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA?
by Nilanjan Banerjee
Court ruling on tariffs fuels market jitters, making low-beta picks like Post, Tencent Music and Kiniksa attractive options.
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
by Zacks Equity Research
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
by Zacks Equity Research
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
by Zacks Equity Research
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
by Zacks Equity Research
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
by Zacks Equity Research
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 26.7% upside potential for Kiniksa Pharmaceuticals International, plc (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas
by Zacks Equity Research
Modine, Tutor Perini, Kiniksa, Life360, and Euroseas show strong price momentum with solid earnings growth outlooks.
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties
by Nalak Das
MOD, TPC, KNSA, LIF and ESEA are defying trade and rate-cut uncertainty with strong recent price momentum and earnings upgrades.
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know
by Zacks Equity Research
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge
by Zacks Equity Research
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 36% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
by Zacks Equity Research
Kiniksa Pharmaceuticals International, plc (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +27.78% and +7.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.